Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Net Cash Flow (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported Net Cash Flow over the past 12 years, most recently at $42.7 million for Q4 2025.

  • Quarterly results put Net Cash Flow at $42.7 million for Q4 2025, up 142.43% from a year ago — trailing twelve months through Dec 2025 was $112.8 million (up 3588.65% YoY), and the annual figure for FY2025 was $112.8 million, up 3588.65%.
  • Net Cash Flow for Q4 2025 was $42.7 million at Viridian Therapeutics, Inc.\DE, down from $52.3 million in the prior quarter.
  • Over the last five years, Net Cash Flow for VRDN hit a ceiling of $312.9 million in Q3 2022 and a floor of -$188.6 million in Q4 2022.
  • Median Net Cash Flow over the past 5 years was $513500.0 (2021), compared with a mean of $8.3 million.
  • Biggest five-year swings in Net Cash Flow: surged 22201.19% in 2021 and later plummeted 2032.6% in 2022.
  • Viridian Therapeutics, Inc.\DE's Net Cash Flow stood at -$96.6 million in 2021, then tumbled by 95.32% to -$188.6 million in 2022, then soared by 95.35% to -$8.8 million in 2023, then tumbled by 1048.49% to -$100.7 million in 2024, then skyrocketed by 142.43% to $42.7 million in 2025.
  • The last three reported values for Net Cash Flow were $42.7 million (Q4 2025), $52.3 million (Q3 2025), and $1.1 million (Q2 2025) per Business Quant data.